Sakai Clinic 62 Founder & Medical Director Mari Sakai Holds Dialogue with Peter Nobel, Chairman of the Nobel Sustainability Trust, Declaring Global Leadership as a Pioneer of Medical Sustainability
TOKYO, Jan. 19, 2026 /PRNewswire/ — Sakai Clinic 62 (Location: Shibuya-ku, Tokyo; Founder & Medical Director: Mari Sakai) announces that Dr. Mari Sakai held a dialogue with Mr. Peter Nobel, Chairman of the Nobel Sustainability Trust (NST), to discuss the international promotion of sustainability within the medical field.
The Nobel Sustainability Trust (NST) is an international foundation established by members of the Nobel family, dedicated to advancing sustainability by bridging scientific research and real-world implementation. During this dialogue, insights from regenerative medicine—including telomere injections and infusions developed by Dr. Sakai—were exchanged alongside NST’s global sustainability philosophy. The discussion revealed strong alignment between both parties and highlighted significant potential for future collaboration.
Dr. Sakai has long advocated that realizing the sustainability of both the human mind and body through regenerative medicine is a critical mission of modern healthcare. Through this dialogue, she further reinforced the importance of communicating the concept of medical sustainability to the international community.
Following the discussion, Dr. Sakai commented:
“This dialogue reaffirmed my strong sense of mission to present the value of medical sustainability to the world and to advance initiatives that safeguard the health and well-being of future generations. As Sakai Clinic 62, we are committed to acting as a pioneer in medical sustainability and will continue to promote these efforts in collaboration with domestic and international networks.”
Sakai Clinic 62 will continue to integrate a global perspective into its initiatives, striving to advance medical sustainability and contribute to the extension of healthy life expectancy and the sustainability of society through regenerative medicine.
Contact Information
8F TOP HILLS GARDEN Dogenzaka,
2-11-6 Dogenzaka, Shibuya-ku, Tokyo 150-0043, Japan
Tel: +81-3-6455-1813
Email: info@sakai-clinic62.jp
Website: https://www.sakai-clinic62.jp/
View original content to download multimedia:https://www.prnewswire.com/news-releases/sakai-clinic-62-founder–medical-director-mari-sakai-holds-dialogue-with-peter-nobel-chairman-of-the-nobel-sustainability-trust-declaring-global-leadership-as-a-pioneer-of-medical-sustainability-302662075.html
SOURCE Sakai Clinic62
You May Also Like
WLFI Expands Into Forex With World Swap Launch
BUZZ HPC Closes Acquisition of 7.2 MW Toronto Site to Build Data Centre for Sovereign AI Infrastructure
BitGo wins BaFIN nod to offer regulated crypto trading in Europe
BitGo’s move creates further competition in a burgeoning European crypto market that is expected to generate $26 billion revenue this year, according to one estimate. BitGo, a digital asset infrastructure company with more than $100 billion in assets under custody, has received an extension of its license from Germany’s Federal Financial Supervisory Authority (BaFin), enabling it to offer crypto services to European investors. The company said its local subsidiary, BitGo Europe, can now provide custody, staking, transfer, and trading services. Institutional clients will also have access to an over-the-counter (OTC) trading desk and multiple liquidity venues.The extension builds on BitGo’s previous Markets-in-Crypto-Assets (MiCA) license, also issued by BaFIN, and adds trading to the existing custody, transfer and staking services. BitGo acquired its initial MiCA license in May 2025, which allowed it to offer certain services to traditional institutions and crypto native companies in the European Union.Read more